Highest-materiality recent filing
Madrigal Q2 Rezdiffra sales $364.3M (+71% YoY); net loss $57.9M
Rezdiffra net sales $364.3M, up 71% from $212.8M in Q2 2025; over 49,000 patients on therapy as of June 30, 2026.
Madrigal Q1 Rezdiffra net sales $311.3M (+127% YoY); pipeline expanded with siRNA deal
Q1 2026 Rezdiffra net sales $311.3M, up 127% YoY from $137.3M; over 42,250 patients on therapy, 2.5x vs Q1 2025.
Madrigal reports Q4 Rezdiffra sales $321M, FY $958M; pipeline expands with siRNA and GLP-1 deals
Q4 2025 Rezdiffra net sales $321.1M; full-year net sales $958.4M, vs $180.1M in 2024.
Madrigal gains full control over Rezdiffra patent term extensions from Roche
Madrigal gets exclusive right to manage all patent term extensions for Rezdiffra, including Roche-owned and joint patents.
Madrigal Q3 2025 Rezdiffra sales $287.3M, annualizing >$1B; licenses oral GLP-1
Rezdiffra net sales $287.3M in Q3 2025 vs $62.2M YoY; >29,500 patients on therapy.
Madrigal Q2 2025: Rezdiffra sales $212.8M, 23k patients; new patent to 2045; $500M credit
Q2 2025 Rezdiffra net sales $212.8M (vs $14.6M prior year); >23,000 patients on therapy as of June 30, 2025.
Madrigal in-licenses oral GLP-1 SYH2086 from CSPC for up to $2B in milestones
Upfront payment of $120M; potential milestone payments up to $2B plus royalties on net sales.
$350M initial term loan funded at close; $150M delayed draw available through Dec 2027.
Madrigal Q1 2025 revenue $137.3M from Rezdiffra; 17,000+ patients on therapy
Net Rezdiffra sales of $137.3M in Q1 2025 vs. $0 in prior-year period as first commercial quarter.
Madrigal Q4 2024 Rezdiffra sales $103.3M; new 2-year data shows benefit in F4c MASH cirrhosis
Q4 and FY 2024 Rezdiffra net sales $103.3M and $180.1M; no product sales in prior year.
Preliminary Q4 2024 Rezdiffra net sales $100M–$103M, full-year $177M–$180M.
Madrigal posts Q3 2024 Rezdiffra net sales of $62.2M; commercial coverage exceeds 80%
Third-quarter 2024 net sales of Rezdiffra $62.2M; no product revenue in prior year.
Madrigal reports Q2 2024 net sales of $14.6M from Rezdiffra launch; cash $1.1B
Rezdiffra U.S. launch generated $14.6M net sales in Q2 2024; no product sales in prior-year period.
Madrigal posts Q1 net loss of ~$147.5M as Rezdiffra launch ramps up
Rezdiffra received FDA accelerated approval on March 14, 2024; first shipments to patients began in April.
Madrigal raises ~$86M from underwriters' option exercise; total offering ~$660M
Underwriters exercised option to purchase 346,153 shares at $260.00 per share.
Madrigal raises ~$574M in public offering for Rezdiffra launch
Offering of 750,000 shares at $260/share and 1,557,692 pre-funded warrants at $259.9999 each.
Madrigal receives FDA accelerated approval for Rezdiffra, first NASH therapy
FDA grants accelerated approval for Rezdiffra in NASH with F2-F3 fibrosis; first approved therapy for NASH.
Madrigal reports Q4 2023 cash of $634M, appoints new CFO, resmetirom PDUFA March 14
Appointed Mardi C. Dier as CFO; previously CFO at Portola, Ultragenyx, and Acelyrin.
Mardi Dier appointed SVP & CFO effective March 11, 2024; previously CFO of Acelyrin (IPO), Ultragenyx, Portola.
Madrigal Q3 operating expenses $98.5M; FDA Priority Review for resmetirom; $500M October financing
FDA accepted NDA for resmetirom, granted Priority Review; PDUFA date March 14, 2024; no advisory committee planned.
Madrigal raises ~$472M in stock/warrant offering to fund resmetirom launch prep
Offering of 1,248,098 shares at $151.69 and 2,048,098 pre-funded warrants at $151.6899 per warrant.
Board adopted Inducement Plan on Sept 8, 2023, reserving 500,000 shares of common stock for equity grants.
FDA accepts Madrigal's NDA for resmetirom for NASH with fibrosis, grants Priority Review
PDUFA target action date set for March 14, 2024; FDA not currently planning an advisory committee meeting.
Madrigal appoints Bill Sibold as President & CEO, effective Sept 8, 2023
Bill Sibold appointed President & CEO effective Sept 8, 2023; also joins Board as Class II director.
Madrigal submits resmetirom NDA for NASH; cash $298.4M as of June 30
Resmetirom NDA submitted to FDA for accelerated approval of NASH with liver fibrosis.
Madrigal completes NDA submission to FDA for resmetirom for NASH with liver fibrosis
Completed rolling NDA submission to FDA for resmetirom for NASH with liver fibrosis; priority review requested.
Madrigal initiates rolling NDA for resmetirom in NASH with liver fibrosis
Initiated rolling NDA submission to FDA seeking accelerated approval for resmetirom for NASH with liver fibrosis.
Madrigal Q1 cash burn $84.1M; resmetirom NDA on track for Q2 2023 with Breakthrough Therapy
Cash and securities $329.5M at March 31, 2023, down from $358.8M at Dec 31, 2022.
Madrigal reports Q4 2022 cash $358.8M; positive Phase 3 NASH results support H1 2023 NDA filing
Cash, cash equivalents and marketable securities $358.8M at Dec 31, 2022, up from $270.3M at Dec 31, 2021.
Madrigal amends credit agreement: rate cut 150bps, extra $15M tranche, $35M draw
Borrowing cost reduced ~150bps to 10.2% as of Feb 3, 2023; interest-only now through May 1, 2025.
Consensus read: NASH resolution 24% (80mg) and 28% (100mg) vs 8% placebo (p<0.0001).
Madrigal raises $259M in equity and $50M debt capacity; NDA submission planned H1 2023
$159M in gross ATM common stock sales and $100M registered direct offering (Series B preferred and common) completed.
Madrigal Phase 3 MAESTRO-NASH meets dual primary endpoints; NDA planned H1 2023
NASH resolution endpoint met: 30% on 100mg vs 10% placebo (p<0.0001); fibrosis improvement: 26% vs 14% (p=0.0002).
Madrigal Q3 cash $153.2M; MAESTRO-NASH topline data on track for Q4 2022
Cash, equivalents and marketable securities $153.2M at Sep 30, 2022, down from $270.3M at Dec 31, 2021.
Madrigal on track for MAESTRO-NASH topline data in Q4 2022; Q2 cash $211.8M
Topline data from Phase 3 MAESTRO-NASH biopsy study expected in Q4 2022; NDA filing planned for H1 2023.
On August 11, 2026, the Board of Directors (the "Board") of Madrigal Pharmaceuticals, Inc. (the "Company") expanded the size of the Board from eight to nine members and, following the recommendation of its Nominating and Governance Committee, elected John C. Reed, M.D., Ph.D. to fill the newly created vacancy on the Board effective as of August 11, 2026.
Pursuant to the Letter Agreement, effective as of April 21, 2025, Dr. Taub will transition from her current role and responsibilities to a new role as a Senior Scientific and Medical Advisor to the Company through the end of 2025.
On March 9, 2025, Fred Craves, Ph.D. provided notice of his resignation from the Board of Directors (the “Board”) of Madrigal Pharmaceuticals, Inc. (the “Company”), effective as of July 1, 2025.
On March 10, 2025, following the recommendation of its Nominating and Governance Committee, the Board expanded the size of the Board from nine to ten members and elected Jackie Fouse, Ph.D. to fill the newly created vacancy.
On February 28, 2024, Madrigal Pharmaceuticals, Inc. (the “Company”) announced the appointment of Mardi C. Dier as Senior Vice President and Chief Financial Officer of the Company, effective March 11, 2024.
Madrigal Pharmaceuticals, Inc. (the “Company”) reports that Remy Sukhija, who has served as the Company’s Chief Commercial Officer since April of 2020, is leaving the Company to pursue other opportunities.
The Board of Directors (the “Board”) of Madrigal Pharmaceuticals, Inc. (the “Company”) appointed Bill Sibold as the President and Chief Executive Officer of the Company, increased the Board size to nine and appointed Bill Sibold as a member of the Board, in each case effective as of 5:01 p.m. ET on September 8, 2023 (the “Start Date”).
As of the Start Date, Dr. Friedman stepped down as Chief Executive Officer but will continue to serve as a director of the Company.
On June 15, 2023, Keith R. Gollust and David Milligan, Ph.D., each Class III directors on the Board of Directors (the “Board”) of Madrigal Pharmaceuticals, Inc. (the “Company”), resigned from the Board, effective immediately.
On June 15, 2023, Julian Baker and Raymond Cheong were appointed to the Board as Class III directors, effective immediately.
On June 15, 2023, Keith R. Gollust and David Milligan, Ph.D., each Class III directors on the Board of Directors (the “Board”) of Madrigal Pharmaceuticals, Inc. (the “Company”), resigned from the Board, effective immediately.
Julian Baker was appointed to serve as the independent Chairman of the Board of Directors.
Max materiality 1.00 · Median 0.75 · Most common event earnings